Prosecution Insights
Last updated: April 19, 2026
Application No. 18/553,311

ANTICANCER COMPOSITION INDUCING CELL SENESCENCE AND CELL DEATH

Non-Final OA §112
Filed
Sep 29, 2023
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Osteoneurogen Inc.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
3y 2m
To Grant
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
824 granted / 1014 resolved
+21.3% vs TC avg
Moderate +9% lift
Without
With
+8.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
56 currently pending
Career history
1070
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
20.9%
-19.1% vs TC avg
§112
41.9%
+1.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1014 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Current Status of 18 / 553311 Claims 1-8 and 25 are examined on the merits. Information Disclosure Statement The information disclosure statement (IDS) submitted on 2023 September 23 was submitted in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 5-8, and 25 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. What groups are attached to a nitrogen atom present in a C5-6-cycloalkyl group for variable R1? Take, for example, a piperidine or piperazine ring. If the nitrogen ring atom is directly attached to the flavone O, its valency is satisfied. However when R1 attaches to a ring atom other than nitrogen in a ring such as piperidine or piperazine, the octet of the nitrogen ring atom will not be filled. This lack of an octet results in a compound of claim 1 being cationic and thus requiring an anion to make a compound of chemical formula I neutral. In this situation what is the corresponding anion to make the compound neutral? Allowable Subject Matter Claims 1, 5-8, and 25 are not allowed. Claims 2-4 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: YOUN (US 20190263789, published 2019 August 29) describes compounds of formula 2-5 (page 4, paragraph [0056]. Although these compounds meet the limitations of chemical formula I, the reference does not suggest using them to treat cancer. These compounds are used to treat fibrosis. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Sep 29, 2023
Application Filed
Feb 20, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595235
PROCESS FOR PRODUCING 4,5-DIHYDRO-1H-PYRAZOLES AND INTERMEDIATES
2y 5m to grant Granted Apr 07, 2026
Patent 12595265
INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
2y 5m to grant Granted Apr 07, 2026
Patent 12588410
ORGANIC ELECTROLUMINESCENT MATERIAL AND METHOD PREPARING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12570660
PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE
2y 5m to grant Granted Mar 10, 2026
Patent 12570626
DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+8.7%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 1014 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month